We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Proteomic Analysis of Urinary Extracellular Vesicles for the Diagnosis of Prostate Cancer

By LabMedica International staff writers
Posted on 30 Apr 2020
A new method for diagnosis of prostate cancer relies on advanced proteomics-based analysis of extracellular vesicles isolated from urine samples.

Extracellular vesicles (EVs) are cell-derived vesicles that are present in many and perhaps all biological fluids, including blood, urine, and cultured medium of cell cultures. More...
The vesicles, which contain RNA, proteins, lipids, and metabolites that are reflective of the cell type of origin, are either released from the cell when multivesicular bodies (MVBs) fuse with the plasma membrane, or they are released directly from the plasma membrane.

EVs are increasingly being recognized as important vehicles of communication between cells and as promising diagnostic and prognostic biomarkers in cancer. Despite the huge clinical potential, the wide variety of methods for separating EVs from biofluids, which provide material of highly variable purity, and the lack of knowledge regarding methodological reproducibility have impeded the entry of EVs into the clinical arena.

In an effort to increase the usefulness of EVs, investigators at Ghent University (Belgium) and colleagues at the University of Turku (Finland) used mass spectrometry-based proteomics to analyze EVs that had been separated and purified from urine by a novel procedure. This density-based fractionation of urine samples obtained from men with benign and malignant prostate disease by bottom-up Optiprep (the iodine-containing non-ionic radiocontrast agent iodixanol) density gradient centrifugation separated EVs and soluble proteins with high specificity and repeatability.

The investigators reported that differential quantitative proteomic analysis of EV-enriched and protein-enriched urine fractions identified unique and biologically and clinically relevant proteomes in urinary EVs. In addition, by profiling matched prostate cancer tissue-derived EVs and urinary EVs, they demonstrated that the urinary EV proteome was a reflection of that of EVs derived from the tissue of origin.

“Detecting and examining these vesicles in urine has an enormous potential for developing new tests for early detection of urological cancers. However, research related to this is still in its infancy,” said first author Bert Dhondt, a researcher in the laboratory for experimental cancer research at Ghent University. “In the future, the results of the study can aid patients with urological cancers through faster diagnosis and timely treatment.”

The proteomic analysis of EVs in the urine of prostate cancer patients was described in the March 11, 2020, online edition of Journal of Extracellular Vesicles.

Related Links:
Ghent University
University of Turku



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.